The Problem

Unlike other companies that are developing technologies to produce Mo-99, Coquí Pharma’s technology is the only proven, demonstrated, safe, and reliable method for commercially scalable Mo-99 production.

Although the U.S. is the world’s largest consumer of medical radioisotopes, it doesn’t have a domestic supply and must rely on imports from Europe and other countries to meet demand. As nuclear reactors around the world continue to age and shut down, securing a reliable commercial source for medical radioisotopes is more important than ever to ensure patients have access to lifesaving diagnostics and treatment.

The Coquí Solution

Coquí Pharma is poised to be the U.S. leader in domestic medical radioisotope production. Coquí Pharma is in the process of licensing and building a dedicated Medical Isotope Production Facility (MIPF) in Oak Ridge, Tennessee. The first of its kind in the U.S., this facility will produce a commercially scalable and reliable source of medical diagnostic and therapeutic radioisotopes, specifically Molybdenum-99 (Mo-99). The facility is expected to be fully operational in 2024.

Unlike other companies that are developing technologies to produce Mo-99, Coquí Pharma’s technology is the only proven, demonstrated, safe, and reliable method for commercially scalable Mo-99 production.

Proven, Reliable Technology

Coquí Pharma has an exclusive license with INVAP, an Argentinian nuclear engineering firm, to use their Low Enriched Uranium (LEU) technology in the United States. INVAP’s reactor is a commercially proven design for Mo-99 production and is the only fully functional research reactor built to utilize LEU. INVAP constructed the OPAL research reactor in Australia and the RA-3 reactor in Argentina.

Proven, Reliable Process

Coquí Pharma employs a previously FDA approved process that will meet more than 50% of the U.S. medical demand for Mo-99. The National Academy of Sciences has recognized Coquí Pharma as the only company among its competitors to get “A” ratings for its proven technology that is compatible with the existing supply chain and uses a licensed reactor design. The technology to be used at Coquí Pharma’s MIPF in Oak Ridge already produces FDA approved medical radioisotopes at ANSTO in Australia.

Proven, Reliable People

Coquí Pharma is backed by a world-class team of leaders and practitioners who possess decades of proven experience across the medical and nuclear radioisotope fields. The company’s board of directors includes experienced operational leaders with deep expertise as CFOs, multinational company CEOs, medical doctors, and former U.S. Nuclear Regulatory Commission officials. Coquí Pharma’s MIPF design and construction is being led by INVAP, the world’s leading designer and developer of LEU Mo-99 production facilities.